BIELLO, FEDERICA
 Distribuzione geografica
Continente #
EU - Europa 1.909
Totale 1.909
Nazione #
IT - Italia 1.909
Totale 1.909
Città #
Genova 1.000
Rapallo 386
Genoa 348
Vado Ligure 169
Bordighera 6
Totale 1.909
Nome #
Uncommon EGFR Exon 19 Mutations Confer Gefitinib Resistance in Advanced Lung Adenocarcinoma 130
Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy 124
Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients 124
Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer 115
Circulating tumor DNA reflects tumor metabolism rather than tumor burden in chemotherapy-naive patients with advanced non–small cell lung cancer:18F-FDG PET/CT study 95
Clinical applications of circulating tumor cells in lung cancer patients by cellsearch system 95
Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study 93
Nivolumab treatment in advanced lung cancer patient with chronic active hepatitis C and systemic lupus erythematosus. 86
Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer 86
New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer 81
Resistin is associated with overall survival in non-small cell lung cancer patients during nivolumab treatment 80
Comparison between 18F-FDG-PET- and CT-based criteria in non-small cell lung cancer (NSCLC) patients treated with Nivolumab 80
The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients 70
Circulating cell-free DNA and circulating tumor cells as prognostic and predictive biomarkers in advanced non-small cell lung cancer patients treated with first-line chemotherapy 66
Vinflunine for the treatment of non-small cell lung cancer 66
Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer 63
CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine 58
Afatinib for the treatment of non-small cell lung cancer 56
The evolving role of pemetrexed disodium for the treatment of non-small cell lung cancer 56
Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy 53
Serum levels of VCAM-1 are associated with survival in patients treated with nivolumab for NSCLC 51
Current state of the art on the diagnosis and the role of target therapy for treatment of ROS1-rearranged non-small cell lung cancer: a narrative review 49
Afatinib and Erlotinib in the treatment of squamous-cell lung cancer 48
Novel approaches for the treatment of unresectable malignant pleural mesothelioma: A focus on immunotherapy and target therapy (Review) 46
Current state of the art and future perspectives with immunotherapy in the management of small cell lung cancer 45
Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy 43
The role of the immune metabolic prognostic index in patients with non-small cell lung cancer (Nsclc) in radiological progression during treatment with nivolumab 32
Improved overall survival in patients developing endocrine toxicity during treatment with nivolumab for advanced non-small cell lung cancer in a prospective study 15
Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab 6
Prognostic relevance of circulating tumor cells and circulating cell-free DNA association in metastatic non-small cell lung cancer treated with nivolumab 4
Totale 2.016
Categoria #
all - tutte 9.356
article - articoli 9.356
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.712


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020213 0 0 0 0 22 29 31 27 26 46 30 2
2020/2021448 11 28 23 157 40 21 11 33 42 37 26 19
2021/2022296 16 8 10 18 14 23 6 63 36 34 15 53
2022/2023431 27 36 8 39 75 68 0 43 65 5 61 4
2023/2024281 7 24 11 36 20 66 14 25 11 26 5 36
2024/2025207 38 43 21 57 48 0 0 0 0 0 0 0
Totale 2.016